No matching results for ''
Tip: Try a valid symbol or a specific company name for relevant results
Canada markets closed
CANADA WEEKLY BRIEF
STAY UP TO DATE WITH THE MOST IMPORTANT CANADIAN BUSINESS AND FINANCE NEWS
Sign up for the Canada Weekly Brief and get all you need to know delivered right to your inbox
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
At close: 4:00PM EDT
580 reactions on $SNY conversation
Sign in to post a message.
If you’re a day trader, you should definitely check out (
). They send a watchlist covering the top pre-market movers every day before the open. It’s a great way to pick out potential trades for the day.
Sanofi’s Covid vaccine is now in its Phase 3 trial, yawn........
It will be very hard for me to buy this stock.I will always remember the dead children in the Philippines who was given the Sanofi Dengue vaccine.More than a dozen,No money could ever buy those lives back.
a competing offer would seem appropiate: market values of BNTX, MRNA, CVAC do not appear to have been a consideration in the pricing of the Sanofi offer. TBIO near the readout of their phase 2/3 covid19 vaccine trial. The current partnership agreement appears to be a better value for a long term TBIO stockholder. There are many big pharma and biotech companies who are in a position to make a better offer.
As long as you have snakes as governors - like in Florida or Texas, which by the way account for over 33% of all new Covid cases - we need more vaccines and we can make money by buying stocks in vaccine making cos. Sanofi is therefore a buy after trying to acquire this new Bio co.
Ugh. $tbio, $sny. Deal negatives: price too low for longs hoping to get more upside from this investment, triggers short term capital gains and taxes for most. Deal positives: cash instead of questionable Sanofi shares, quickly monetizes upside for longs without any more waiting for good news. Guess longs can only take their chips and move on to another table; this game is done.
a successful mRNA vaccine in covid19 or influenza would be a tremendous value to current shareholders. A discounted cash flow of that success would value the company closer to other mRNA companies with successful a drug. I took that gamble
Sanofi to acquire Translate Bio; advances deployment of mRNA technology across vaccines and therapeutics development
French drug maker Sanofi says it will help manufacture 125 million doses of the coronavirus vaccine developed by rivals Pfizer and BioNTech, while its own vaccine candidate faces delays.
Watch for this to pop in the EU, as MRNA being looked at more carefully for adverse reaction
French-made Sanofi Covid vaccine moves a step closer to use in EU
Per Market Beat; SNY had its price target raised by analysts at HC Wainwright from $703.00 to $729.00. They now have a "buy" rating on the stock. This represents a 1316.4% upside from the current price of $51.47.
"If you don’t get vaccinated, you will get Covid at this point’: Doctor"
More fear mongering DEMO-NONSENSE.
Goldman Sachs Group Inc. increased its stake in shares of Translate Bio, Inc. (NASDAQ:TBIO) by 62.2% in the 1st qtr. The firm owned 1,592,511 shares of the company’s stock after buying an additional 610,590 shares during the quarter. Goldman Sachs Group Inc.’s holdings in Translate Bio were worth $26,261,000 at the end of the most recent reporting period.
SNY market cap 129 billion shares outstanding 2.50 billion employees 99412 share price 51,76$
Sanofi still doesn't have a COVID-19 vaccine on the horizon, the analyst ratings on this stock are......drum roll please......
Thank you ladies and gentlemen for buying KDMN have a nice day
Compared to Pfizer, Moderna and AZ this stock is worth about 75#$%$
Regret buying this stock...
Trump NYC Tower Debt Hits Watch List With Vacancies Rising
How Canadians can invest in real estate without buying a home
Yahoo Finance Canada
These are the top companies Canadian students want to work for
Yahoo Finance Canada
© 2021 Verizon Media. All rights reserved.
About Our Ads